NMPA released the revised Good Manufacturing Practice (GMP) for Medical Devices on November 4, 2025, also referred to as the “Specification for Medical Device Production.” This marks the most substantial update to China’s device manufacturing regulation since the original 2014 version.
The new GMP will be fully implemented on November 1, 2026. Referenced from international standards such as ISO 13485, the EU Medical Device Regulation (MDR), and the FDA Quality System Regulation (QMSR/21 CFR 820), the revised GMP reflects China’s broader strategy of aligning domestic regulatory expectations with global best practices while strengthening oversight of supply chains, digital systems, and outsourced activities.
For overseas manufacturers—even those producing devices entirely outside China—the implications are far-reaching. Registration expectations, supply chain cooperation with Chinese partners, and local manufacturing or finishing arrangements will increasingly be assessed against this updated GMP regulation.
For our old NMPA GMP training webinar in January 2017, please click HERE
NMPA resumes overseas on-site inspections after Covid-19 pause. Click HERE to learn more
For 2025 regulation of “Production of Imported Medical Devices”, please click HERE
For our comprehensive review on the “Made-in-China” policy, click HERE
Overview of 2025 GMP Framework
At a structural level, the revised GMP represents a major expansion in scope and regulatory depth.
Key high-level updates include:
- Effective date: November 1, 2026
- Structural expansion: Reorganized into 15 chapters and 132 articles
- Scope extension: Full lifecycle coverage, including outsourced R&D, contract manufacturing, external processing, and entrusted testing
- Compliance focus: Stronger requirements for quality assurance, personnel qualifications, facilities, supplier management, and digital documentation
- Applicability: Impacts both domestic manufacturers and overseas companies using Chinese partners or supply-chain services
Compared to the 2014 version, which primarily emphasized production-stage quality control, the new GMP shifts toward end-to-end lifecycle governance, integrating design, risk management, post-market feedback, and supplier oversight into a unified regulatory framework.
This transformation reflects China’s regulatory modernization agenda and its push toward high-quality, innovation-driven manufacturing under national industrial policies such as “Made in China” and intelligent manufacturing initiatives.
What’s New? Three Newly Introduced Chapters on Quality Assurance, Validation and Verification, and Contract Manufacturing
One of the most structural changes in China’s 2025 GMP revision is the formal introduction of three new standalone chapters dedicated to Quality Assurance, Validation and Verification, and Contract Manufacturing and Outsourced Activities. Unlike the 2014 GMP, where these topics were scattered across general production requirements, the new framework elevates them into independent regulatory modules with clearer accountability, prescriptive controls, and inspection-ready expectations. Together, these additions reflect the regulator’s shift toward system-level quality governance, process reliability assurance, and full supply chain transparency.
The newly added Quality Assurance (QA) chapter establishes QA as a core governance function rather than a supporting operational role. The regulation requires manufacturers to build a structured, management-driven quality oversight system that spans the full product lifecycle. Key regulatory expectations include:
- Establishment of a formal QA system covering design, production, distribution, and post-market activities
- Lifecycle risk management supported by continuous data collection, trend analysis, and periodic management review
- Structured change control mechanisms requiring documented risk assessment, approval workflows, and verification when applicable
- Clear assignment of management responsibilities for quality decision-making and regulatory compliance
This change significantly increases leadership accountability and reinforces the independence of quality functions from production operations. For overseas manufacturers working with Chinese OEMs or local manufacturing partners, it also raises expectations for quality agreements, audit coordination, and alignment between global QMS frameworks and China-specific GMP documentation.
The newly introduced Validation and Verification chapter strengthens regulatory control over manufacturing reproducibility and technical consistency. Rather than focusing only on end-product inspection, the revised GMP emphasizes scientific validation of critical processes and systematic verification of design and production outputs. Manufacturers are now expected to:
- Validate critical production processes and special processes that cannot be fully verified through routine inspection
- Maintain documented evidence of equivalency when transferring technologies across sites or jurisdictions
- Perform revalidation following significant changes in equipment, materials, software, or production parameters
- Integrate validation activities into formal lifecycle change management systems
For multinational companies implementing parallel manufacturing lines or transferring production from overseas facilities to China, this means higher scrutiny of process comparability studies, performance qualification data, and cross-site validation strategies. Regulators increasingly expect manufacturers to demonstrate not only functional compliance, but long-term process stability under commercial-scale production conditions.
In parallel, the addition of a dedicated Contract Manufacturing and Outsourced Activities chapter formally brings external production and service providers under direct GMP regulatory control. Activities such as outsourced R&D, sterilization services, packaging operations, external processing, and entrusted testing are now explicitly regulated within the GMP framework. The regulation clearly defines that registrants retain ultimate responsibility for compliance performance across the entire supply chain. Core requirements include:
- Mandatory quality agreements defining technical responsibilities, quality standards, deviation handling, and change notification procedures
- Two-way oversight mechanisms, including routine audits, performance monitoring, and corrective action tracking
- Formal communication channels for reporting deviations, complaints, and quality incidents
- Clear separation of production release responsibilities and market release authority, which cannot be subcontracted
For overseas manufacturers relying on Chinese contract manufacturers, sterilization providers, packaging facilities, or testing laboratories, this introduces higher expectations for supplier qualification, documentation harmonization, audit readiness, and cross-border quality governance structures. Supply chain transparency is increasingly becoming a primary inspection focus rather than a secondary compliance element.
Taken together, the addition of these three new chapters signals a decisive regulatory upgrade in China’s GMP system. Quality governance, validation discipline, and outsourced manufacturing control are now positioned as independent but interconnected regulatory pillars. Overseas manufacturers will need to move beyond fragmented compliance approaches and adopt an integrated, lifecycle-oriented quality strategy to remain competitive and inspection-ready under China’s evolving GMP environment.
Lifecycle Management
One of the most significant conceptual changes in the 2025 GMP is the formal introduction of a full product lifecycle management mindset. Rather than treating manufacturing as an isolated compliance activity, the regulation requires manufacturers to demonstrate continuous quality and risk control from early-stage design through commercialization and post-market surveillance.
Lifecycle coverage now explicitly includes:
- Design and development planning
- Risk analysis and mitigation
- Process validation and equipment qualification
- Supplier and material control
- Batch release and distribution management
- Post-market feedback integration
- Change management and continuous improvement
For multinational companies transferring technology to China or collaborating with Chinese partners, this means greater scrutiny of design history files, risk management reports, and traceability documentation. Regulatory reviewers increasingly expect consistent logic across pre-market registration materials and manufacturing quality systems.
Design and Development Controls
The 2025 GMP significantly strengthens requirements for design and development control, bringing China closer to mature regulatory systems in the US and EU.
The regulation emphasizes:
- Structured design planning and documentation
- Clear definition of design inputs and outputs
- Formal verification and validation activities
- Robust design transfer procedures to ensure manufacturability
- Oversight of outsourced design partners
Design transfer is particularly important for overseas companies that develop products abroad but manufacture in China. Regulators now expect clear evidence that design outputs can be reliably and consistently scaled into commercial production.
For companies relying on third-party R&D service providers, the GMP makes it clear that contracting firms are responsible for verifying partner capabilities and output quality.
Qualification Requirements for Key Personnel
The updated GMP introduces more prescriptive qualification standards for personnel in key management and quality roles.
Key requirements include:
- A qualified management representative for Class II and III devices with a relevant bachelor’s degree or equivalent technical title and at least three years of experience
- Equivalent qualification requirements for heads of quality management
- Full-time staffing requirements for legal representatives, management representatives, and quality leads
- Separation of production leadership and quality management roles
This change reflects the regulator’s focus on professional accountability and organizational independence of quality oversight. Overseas manufacturers working with Chinese partners should verify that local teams meet these updated competency thresholds to avoid compliance risks during audits or inspections.
Facility, Environmental, and Infrastructure Controls
Facility management requirements under the 2025 GMP are significantly more detailed than before.
The regulation specifies:
- Defined cleanroom pressure differentials (for example, >10 Pa between clean and non-clean areas)
- Layout requirements to prevent cross-contamination and material mix-ups
- Access restrictions for production, testing, and storage areas
- Suitability of IT infrastructure to support controlled production and quality operations
These changes may require physical upgrades, requalification activities, or layout adjustments for manufacturers operating in China. For overseas firms establishing local production or packaging facilities, facility planning should incorporate these regulatory parameters early in project design.
Equipment and Instrument Control
The revised GMP formalizes full lifecycle management requirements for equipment and measuring instruments.
Manufacturers must demonstrate:
- Documented procurement, installation, and qualification records
- Regular calibration and verification covering actual operating ranges
- Clear status identification to prevent misuse
- Requalification following major repairs or process modifications
This aligns closely with global expectations and supports more reliable manufacturing performance. Companies should review equipment management procedures and calibration programs to ensure compliance with the expanded documentation and traceability requirements.
Digital Documentation and Data Requirements
The 2025 GMP formally recognizes electronic records and electronic signatures, while introducing clearer expectations for data integrity and system security.
Key provisions include:
- User access control with full audit trails
- Logging of data changes and deletions
- Mandatory data backup and retention procedures
- Guaranteed data readability throughout the retention period
- Controlled document lifecycle management
As China promotes intelligent manufacturing and digital traceability systems such as Unique Device Identification (UDI), regulators increasingly expect manufacturers to demonstrate secure, traceable, and auditable digital workflows.
Overseas manufacturers using global electronic QMS platforms should verify that system configurations meet Chinese regulatory expectations, particularly regarding audit trails, access rights, and localized document control processes.
Risk-Based Supplier and Procurement Management
Supplier oversight is now governed by a more formalized risk-based classification framework.
The new GMP requires manufacturers to:
- Categorize suppliers based on impact on product quality and safety
- Establish detailed quality agreements defining responsibilities and technical requirements
- Receive advance notification of supplier changes affecting critical materials or processes
- Conduct on-site audits based on risk assessment
This change increases documentation and auditing workload but improves overall supply chain transparency. Overseas manufacturers working with Chinese component suppliers should ensure supplier qualification programs are aligned with these structured expectations.
Comparison Overview: 2014 GMP vs. 2025 GMP
| Regulatory Area | 2014 GMP | 2025 GMP (Effective Nov 2026) |
| Structure | Limited chapters with general requirements | Expanded to 15 chapters and 132 articles with prescriptive detail |
| Lifecycle Scope | Focused mainly on production | Full lifecycle coverage including outsourced R&D and post-market activities |
| Quality Assurance | General QMS framework | Dedicated QA chapter with structured change control and lifecycle risk management |
| Personnel Requirements | Basic competency expectations | Defined education and experience thresholds; full-time key roles; role separation |
| Facility Controls | Broad cleanroom guidance | Defined pressure differentials, layout restrictions, and IT infrastructure suitability |
| Equipment Management | Basic calibration requirements | Full equipment lifecycle documentation and mandatory requalification |
| Digital Documentation | Electronic records permitted but vague | Formal recognition with audit trails, access control, and data integrity rules |
| Design Controls | Limited requirements | Structured design control, strengthened design transfer, and outsourced R&D oversight |
| Supplier Management | Basic oversight | Risk-based classification, mandatory quality agreements, structured audits |
| Contract Manufacturing | Responsibilities unclear | Defined accountability, two-way oversight, separation of production vs. market release |
| Compliance Threshold | Less prescriptive | Higher regulatory expectations requiring system upgrades |
Practical Transition Strategy for Overseas Manufacturers
With the regulation becoming mandatory in November 2026, a phased transition approach is recommended.
Preparation Phase (Now – September 2026)
- Establish a dedicated GMP transition task force
- Conduct gap analysis against current systems
- Provide regulatory training to quality and operations teams
- Develop a resource and timeline roadmap
- Update QMS procedures and supplier controls
- Execute validation and verification upgrades
- Finalize documentation and contract manufacturing agreements
- Implement digital system improvements
Implementation Phase (From October 2026)
- Perform internal audits against the new GMP
- Close identified nonconformities
- Establish continuous improvement programs
- Maintain periodic training and management review cycles
Early preparation significantly reduces compliance risk and avoids last-minute operational disruptions. China Med Device, LLC helps overseas manufacturers navigate regulatory updates, evaluate compliance readiness, and build quality systems aligned with China’s GMP environment and your inspection needs.
For support with GMP transition planning or readiness gap assessments, please email us at info@ChinaMedDevice.com